CCNE1 Amplification

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Endometrial Carcinoma1
CCNE1 Amplification	Camonsertib + LunresertibCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID12762 In endometrial carcinoma (EMCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500), with ~80% growth inhibition at low-dose comb… (full text at CIViC) PMID 40169546 · Xu et al., 2025 · Open in CIViC	civic
Endometrial Serous Adenocarcinoma1
CCNE1 Amplification	Fadraciclib + TaselisibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID10181

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Endometrial Carcinoma1

CCNE1 Amplification

Camonsertib + LunresertibCombination

Predictive

Supports Sensitivity Response

accepted

EID12762

In endometrial carcinoma (EMCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500), with ~80% growth inhibition at low-dose comb… (full text at CIViC)

PMID 40169546 · Xu et al., 2025 · Open in CIViC

civic

Endometrial Serous Adenocarcinoma1

CCNE1 Amplification

Fadraciclib + TaselisibCombination

Predictive

Supports Sensitivity Response

submitted

EID10181

Malignant Gastric Neoplasm1
CCNE1 Amplification	(prognostic)	Prognostic	C	Supports Poor Outcome	3	submitted	EID7437 CCNE1 amplification has been found in 11–12% of gastric cancers and recent studies have shown that CCNE1 amplification is significantly associated with liver metastasis in a TP53-mutated gastric cance… (full text at CIViC) PMID 31178228 · Kim et al., 2019 · Open in CIViC	civic

Malignant Gastric Neoplasm1

CCNE1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID7437

CCNE1 amplification has been found in 11–12% of gastric cancers and recent studies have shown that CCNE1 amplification is significantly associated with liver metastasis in a TP53-mutated gastric cance… (full text at CIViC)

PMID 31178228 · Kim et al., 2019 · Open in CIViC

civic

Malignant Ovarian Neoplasm2
CCNE1 Amplification	Dinaciclib	Predictive	D	Supports Sensitivity Response	1	submitted	EID7791 Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis. PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC	civic
CCNE1 Amplification	Cisplatin + DinaciclibCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID7799 Researchers tested the combination of dinaciclib + cisplatin in ovarian cancer cell lines and xenografts. p53 (-,-) mouse ovarian surface epithelial cells were transformed either by a CCNE1 transgene… (full text at CIViC) PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC	civic

Malignant Ovarian Neoplasm2

CCNE1 Amplification

Dinaciclib

Predictive

Supports Sensitivity Response

submitted

EID7791

Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis.

PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC

civic

CCNE1 Amplification

Cisplatin + DinaciclibCombination

Predictive

Supports Sensitivity Response

submitted

EID7799

Researchers tested the combination of dinaciclib + cisplatin in ovarian cancer cell lines and xenografts. p53 (-,-) mouse ovarian surface epithelial cells were transformed either by a CCNE1 transgene… (full text at CIViC)

PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC

civic

Ovarian Carcinoma2
CCNE1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID466 In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival. PMID 20336784 · Nakayama et al., 2010 · Open in CIViC	civic
CCNE1 Amplification	Camonsertib + LunresertibCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID12761 In ovarian carcinoma (OVCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500). CCNE1 copy number correlates with synergy by MTT… (full text at CIViC) PMID 40169546 · Xu et al., 2025 · Open in CIViC	civic

Ovarian Carcinoma2

CCNE1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID466

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

civic

CCNE1 Amplification

Camonsertib + LunresertibCombination

Predictive

Supports Sensitivity Response

accepted

EID12761

In ovarian carcinoma (OVCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500). CCNE1 copy number correlates with synergy by MTT… (full text at CIViC)

PMID 40169546 · Xu et al., 2025 · Open in CIViC

civic

Ovarian Serous Cystadenocarcinoma1
CCNE1 Amplification	Akt Inhibitor MK2206 + DinaciclibCombination	Predictive	D	Supports Sensitivity Response	4	accepted	EID1735 A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC	civic

Ovarian Serous Cystadenocarcinoma1

CCNE1 Amplification

Akt Inhibitor MK2206 + DinaciclibCombination

Predictive

Supports Sensitivity Response

accepted

EID1735

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC

civic

Estrogen Receptor-positive Breast Cancer1unmapped disease
CCNE1 Amplification	Palbociclib	Predictive	D	Supports Resistance	3	accepted	EID1629 Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were de… (full text at CIViC) PMID 27020857 · Herrera-Abreu et al., 2016 · Open in CIViC	civic

Estrogen Receptor-positive Breast Cancer1unmapped disease

CCNE1 Amplification

Palbociclib

Predictive

Supports Resistance

accepted

EID1629

Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were de… (full text at CIViC)

PMID 27020857 · Herrera-Abreu et al., 2016 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (0)